MXPA05011296A - Conjugados de fosfonato inhibidores de la cinasa. - Google Patents
Conjugados de fosfonato inhibidores de la cinasa.Info
- Publication number
- MXPA05011296A MXPA05011296A MXPA05011296A MXPA05011296A MXPA05011296A MX PA05011296 A MXPA05011296 A MX PA05011296A MX PA05011296 A MXPA05011296 A MX PA05011296A MX PA05011296 A MXPA05011296 A MX PA05011296A MX PA05011296 A MXPA05011296 A MX PA05011296A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitor
- compounds
- phosphonate conjugates
- inhibitor phosphonate
- conjugates
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46546503P | 2003-04-25 | 2003-04-25 | |
| US46559403P | 2003-04-25 | 2003-04-25 | |
| US46556903P | 2003-04-25 | 2003-04-25 | |
| US46558803P | 2003-04-25 | 2003-04-25 | |
| US49538203P | 2003-08-15 | 2003-08-15 | |
| US49568603P | 2003-08-15 | 2003-08-15 | |
| US49568503P | 2003-08-15 | 2003-08-15 | |
| US49552703P | 2003-08-15 | 2003-08-15 | |
| US51432403P | 2003-10-24 | 2003-10-24 | |
| US51433003P | 2003-10-24 | 2003-10-24 | |
| US51395603P | 2003-10-24 | 2003-10-24 | |
| US51397403P | 2003-10-24 | 2003-10-24 | |
| US51420703P | 2003-10-24 | 2003-10-24 | |
| US51436803P | 2003-10-24 | 2003-10-24 | |
| US51392503P | 2003-10-24 | 2003-10-24 | |
| US51411503P | 2003-10-24 | 2003-10-24 | |
| US53193203P | 2003-12-22 | 2003-12-22 | |
| US53605404P | 2004-01-12 | 2004-01-12 | |
| PCT/US2004/013062 WO2004096234A2 (en) | 2003-04-25 | 2004-04-26 | Kinase inhibitor phosphonate conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05011296A true MXPA05011296A (es) | 2006-01-24 |
Family
ID=33425953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05011296A MXPA05011296A (es) | 2003-04-25 | 2004-04-26 | Conjugados de fosfonato inhibidores de la cinasa. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7417055B2 (enExample) |
| EP (1) | EP1620109A2 (enExample) |
| JP (2) | JP2006524710A (enExample) |
| KR (1) | KR20060022647A (enExample) |
| AU (1) | AU2004233897A1 (enExample) |
| CA (1) | CA2522845A1 (enExample) |
| EA (1) | EA200501676A1 (enExample) |
| MX (1) | MXPA05011296A (enExample) |
| NO (1) | NO20055590L (enExample) |
| WO (1) | WO2004096234A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI332956B (en) | 2002-04-26 | 2010-11-11 | Gilead Sciences Inc | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds |
| US7141035B2 (en) * | 2003-03-28 | 2006-11-28 | Sherwood Services Ag | Catheter with occlusion resistant tip |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| EP1620109A2 (en) | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| AU2004233898B2 (en) | 2003-04-25 | 2010-12-23 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| EP4032897B1 (en) | 2003-05-30 | 2025-01-29 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| AU2004286239A1 (en) | 2003-10-24 | 2005-05-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
| NO20035682D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av ösofagkreft og Barretts ösofag |
| NO20035681D0 (no) * | 2003-12-18 | 2003-12-18 | Amersham Health As | Optisk avbildning av lungekreft |
| AU2004308974A1 (en) * | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| MXPA06006899A (es) | 2003-12-22 | 2006-09-04 | Gilead Sciences Inc | Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c. |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| ES2363160T3 (es) | 2004-07-27 | 2011-07-22 | Gilead Sciences, Inc. | Conjugados de fosfonato nucelosidico como agentes anti-vih. |
| WO2006031725A2 (en) | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| MX2008001334A (es) * | 2005-07-29 | 2008-03-24 | Pfizer Prod Inc | Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y sintesis. |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| JP2010522163A (ja) * | 2007-03-20 | 2010-07-01 | キュリス，インコーポレイテッド | 亜鉛結合部位を含むＲａｆキナーゼインヒビター |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| JP5620376B2 (ja) | 2008-07-08 | 2014-11-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ阻害剤化合物の塩 |
| NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| SG172359A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside phosphoramidates |
| MX2011009498A (es) | 2009-03-11 | 2011-10-14 | Ardea Biosciences Inc | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos. |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
| EP2552203B1 (en) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| WO2012068483A1 (en) | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment based on hypoxic status |
| AU2011330730B2 (en) | 2010-11-18 | 2016-02-18 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
| JP2014503500A (ja) | 2010-11-18 | 2014-02-13 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択 |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| AP2015008328A0 (en) | 2012-10-16 | 2015-03-31 | Almirall Sa | Pyrrolotriazinone derivatives as pi3k inhibitors |
| WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| JP6851978B2 (ja) | 2015-04-20 | 2021-03-31 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ミトコンドリアプロファイリングによるアルボシジブ応答の予測 |
| JP6510075B2 (ja) | 2015-05-18 | 2019-05-08 | トレロ ファーマシューティカルズ， インコーポレイテッド | バイオアベイラビリティが高いアルボシジブプロドラッグ |
| EP3331510A4 (en) | 2015-08-03 | 2019-04-03 | Tolero Pharmaceuticals, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| CN109071467B (zh) | 2016-03-09 | 2023-04-04 | 艾丽奥斯生物制药有限公司 | 无环抗病毒药 |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CA3047557A1 (en) | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
| ES2892402T3 (es) | 2017-08-01 | 2022-02-04 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2001A (en) * | 1841-03-12 | Sawmill | ||
| DK159431C (da) * | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler |
| IE63869B1 (en) | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| FR2611203B1 (fr) | 1987-02-20 | 1989-06-09 | Sturtz Georges | Analogues gem-diphosphoniques d'amethopterine (methotrexate) et de derives deaza-n-10 amethopterine. leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
| DE4003574A1 (de) | 1990-02-07 | 1991-08-08 | Bayer Ag | Neue dipeptide, verfahren zu ihrer herstellung und ihre verwendung als renininhibitoren in arzneimitteln |
| DE69115694T2 (de) | 1990-06-13 | 1996-10-17 | Arnold Newton Mass. Glazier | Phosphorylierte prodrugs |
| DE69116750T2 (de) | 1990-07-04 | 1996-11-14 | Merrell Dow Pharma | 9-Purinyl-Phosphonsäurederivate |
| US5177064A (en) * | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| DE4111730A1 (de) | 1991-04-10 | 1992-10-15 | Knoll Ag | Neue cytarabin-derivate, ihre herstellung und verwendung |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| EP0531597A1 (en) | 1991-09-12 | 1993-03-17 | Merrell Dow Pharmaceuticals Inc. | Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine |
| US5610294A (en) | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
| GB9126144D0 (en) | 1991-12-10 | 1992-02-12 | British Bio Technology | Compounds |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US5654286A (en) | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| EP0632048B1 (en) | 1993-06-29 | 2001-03-21 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
| WO1995002582A1 (en) * | 1993-07-14 | 1995-01-26 | Ciba-Geigy Ag | Cyclic hydrazine compounds |
| US5663279A (en) * | 1993-08-24 | 1997-09-02 | Akzo Nobel Nv | Ophthalmic lenses |
| US5446137B1 (en) * | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5493030A (en) | 1994-02-18 | 1996-02-20 | Syntex (U.S.A.) Inc. | 5-substituted derivatives of mycophenolic acid |
| US5854227A (en) * | 1994-03-04 | 1998-12-29 | Hartmann; John F. | Therapeutic derivatives of diphosphonates |
| DK0786455T3 (da) | 1994-09-26 | 2004-03-29 | Shionogi & Co | Imidazolderivater |
| WO1996014314A2 (en) | 1994-11-04 | 1996-05-17 | Gilead Sciences, Inc. | Thiepane compounds inhibiting and detecting hiv protease |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6299496A (en) | 1995-06-29 | 1997-01-30 | Novo Nordisk A/S | Novel substituted azabicyclic compounds |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| EP0852233A4 (en) | 1995-09-21 | 1999-09-15 | Nippon Shinyaku Co Ltd | CYCLOSPORIN PHOSPHATE DERIVATIVES AND MEDICINAL COMPOSITION |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5874577A (en) * | 1996-04-03 | 1999-02-23 | Medichem Research, Inc. | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof |
| JP4033494B2 (ja) | 1996-07-26 | 2008-01-16 | ギリヤド サイエンシーズ， インコーポレイテッド | ヌクレオチドアナログ |
| ES2186911T3 (es) | 1996-08-13 | 2003-05-16 | Mitsubishi Chem Corp | Compuestos nucleotidico de fosfonato. |
| WO1998011906A1 (en) | 1996-09-17 | 1998-03-26 | Amur Pharmaceuticals, Inc. | Phospholipid drug derivatives |
| KR100560182B1 (ko) | 1996-10-09 | 2006-03-13 | 파마셋 인코포레이티드 | 비스포스포네이트 화합물 |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6174888B1 (en) | 1998-05-28 | 2001-01-16 | Novartis Ag | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones |
| AU4125099A (en) | 1998-06-01 | 1999-12-20 | S & T Science And Technology Inc. | Antiviral phosphorus derivatives of 4'-thio-5-ethyl-2'-deoxyuridine |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| TWI260322B (en) | 1999-02-12 | 2006-08-21 | Vertex Pharma | Inhibitors of aspartyl protease |
| IL145052A0 (en) | 1999-03-05 | 2002-06-30 | Metabasis Therapeutics Inc | Novel phosphorus-containing prodrugs |
| US6258831B1 (en) | 1999-03-31 | 2001-07-10 | The Procter & Gamble Company | Viral treatment |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| DE60005017T2 (de) | 1999-06-25 | 2004-06-09 | Vertex Pharmaceuticals Inc., Cambridge | Prodrugs von impdh-inhibierenden carbamaten |
| MXPA02001857A (es) | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
| GB9920872D0 (en) | 1999-09-04 | 1999-11-10 | Glaxo Group Ltd | Benzophenones as inhibitors of reverse transcriptase |
| IL131887A0 (en) | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| MXPA02005490A (es) | 1999-12-03 | 2004-09-10 | Univ California San Diego | Compuestos de fosfonato. |
| JP2003518128A (ja) | 1999-12-22 | 2003-06-03 | メルク フロスト カナダ アンド カンパニー | タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなる芳香族ホスホネート |
| KR20020093824A (ko) * | 2000-02-29 | 2002-12-16 | 미쯔비시 웰 파마 가부시키가이샤 | 포스포네이트 뉴클레오티드 화합물 |
| HUP0301713A3 (en) | 2000-06-13 | 2005-04-28 | Shionogi & Co | Pharmaceutical compositions containing propenone derivatives and their use |
| FR2810322B1 (fr) | 2000-06-14 | 2006-11-10 | Pasteur Institut | PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP) |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| US6617310B2 (en) | 2000-07-19 | 2003-09-09 | Bristol-Myers Squibb Pharma Company | Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines |
| EP2682397B1 (en) | 2000-07-21 | 2017-04-19 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| US6420586B1 (en) | 2000-08-15 | 2002-07-16 | University Of Kansas | Amino acid-derived cyclic phosphonamides and methods of synthesizing the same |
| GB0028429D0 (en) * | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| BR0116221A (pt) | 2000-12-15 | 2005-09-13 | Pharmasset Ltd | Agentes antivirais para tratamento de infecções por flaviviridae |
| HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| JP2004535193A (ja) | 2001-06-20 | 2004-11-25 | ヌエヴォリューション・アクティーゼルスカブ | 鋳型化された分子およびかかる分子の使用方法 |
| KR20020097384A (ko) * | 2001-06-20 | 2002-12-31 | 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 | 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제 |
| JP2005508924A (ja) | 2001-08-30 | 2005-04-07 | 三菱ウェルファーマ株式会社 | 抗ウイルス剤 |
| KR20050044587A (ko) | 2001-12-07 | 2005-05-12 | 미쯔비시 웰 파마 가부시키가이샤 | Ｂ형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도 |
| CA2470423C (en) | 2001-12-21 | 2011-03-15 | Guilford Pharmaceuticals, Inc. | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| AU2003210787B2 (en) | 2002-02-01 | 2009-04-23 | Medinol Ltd. | Phosphorus-containing compounds & uses thereof |
| ATE433961T1 (de) | 2002-02-08 | 2009-07-15 | Conforma Therapeutics Corp | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
| WO2003080078A1 (en) | 2002-03-18 | 2003-10-02 | Mitsubishi Pharma Corporation | Treatment of pre-core hepatitis b virus mutant infections |
| TWI332956B (en) | 2002-04-26 | 2010-11-11 | Gilead Sciences Inc | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds |
| PL219609B1 (pl) | 2003-02-19 | 2015-06-30 | Masanori Baba | Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania |
| US7452901B2 (en) * | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| EP1620109A2 (en) | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
-
2004
- 2004-04-26 EP EP04750806A patent/EP1620109A2/en not_active Withdrawn
- 2004-04-26 CA CA002522845A patent/CA2522845A1/en not_active Abandoned
- 2004-04-26 KR KR1020057020117A patent/KR20060022647A/ko not_active Withdrawn
- 2004-04-26 WO PCT/US2004/013062 patent/WO2004096234A2/en not_active Ceased
- 2004-04-26 EA EA200501676A patent/EA200501676A1/ru unknown
- 2004-04-26 JP JP2006513386A patent/JP2006524710A/ja not_active Withdrawn
- 2004-04-26 US US10/832,811 patent/US7417055B2/en not_active Expired - Fee Related
- 2004-04-26 AU AU2004233897A patent/AU2004233897A1/en not_active Abandoned
- 2004-04-26 MX MXPA05011296A patent/MXPA05011296A/es not_active Application Discontinuation
-
2005
- 2005-11-25 NO NO20055590A patent/NO20055590L/no not_active Application Discontinuation
-
2007
- 2007-04-24 JP JP2007114889A patent/JP2007291111A/ja not_active Withdrawn
-
2008
- 2008-07-02 US US12/167,038 patent/US20090181930A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004233897A1 (en) | 2004-11-11 |
| KR20060022647A (ko) | 2006-03-10 |
| JP2006524710A (ja) | 2006-11-02 |
| NO20055590L (no) | 2006-01-24 |
| CA2522845A1 (en) | 2004-11-11 |
| US20090181930A1 (en) | 2009-07-16 |
| NO20055590D0 (no) | 2005-11-25 |
| US7417055B2 (en) | 2008-08-26 |
| WO2004096234A2 (en) | 2004-11-11 |
| JP2007291111A (ja) | 2007-11-08 |
| US20050261253A1 (en) | 2005-11-24 |
| EP1620109A2 (en) | 2006-02-01 |
| WO2004096234A3 (en) | 2005-01-27 |
| EA200501676A1 (ru) | 2006-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05011296A (es) | Conjugados de fosfonato inhibidores de la cinasa. | |
| WO2005002626A3 (en) | Therapeutic phosphonate compounds | |
| TW200618804A (en) | Phosphonate analogs of HIV inhibitor compounds | |
| WO2004096285A3 (en) | Anti-infective phosphonate conjugates | |
| TW200614996A (en) | Antiviral compounds | |
| BRPI0418031A (pt) | inibidores de quinase fosfonato-substituìdos | |
| MXPA03010207A (es) | Nuevas 4-anilinoquinolin-3-carboxamidas. | |
| MXPA05012025A (es) | Imidazo y tiazolopiridinas como inhibidores de cinasa jak3. | |
| WO2004096286A3 (en) | Antiviral phosphonate analogs | |
| TW200738741A (en) | Antiviral compounds | |
| TW200738742A (en) | Antiviral compounds | |
| WO2004096233A3 (en) | Nucleoside phosphonate conjugates | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| MXPA05012026A (es) | Compuestos de azaindol como inhibidores de cinasa. | |
| TW200510407A (en) | Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors | |
| CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| MXPA05011294A (es) | Compuestos de fosfonato anti-inflamatorios. | |
| WO2004096287A3 (en) | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | |
| MXPA04006266A (es) | Pirimidotriazinas como inhibidores de fosfatasa. | |
| WO2007014352A3 (en) | Antiviral phosphonate conjugates for inhibition of hiv | |
| TW200616977A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
| MXPA05011289A (es) | Compuestos de fosfato que tienen actividad inmunomoduladora. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |